DBV Technologies S.A. $DBVT Shares Sold by Redmile Group LLC

Redmile Group LLC cut its stake in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 10.6% during the first quarter, Holdings Channel reports. The firm owned 491,340 shares of the company’s stock after selling 58,500 shares during the quarter. DBV Technologies makes up approximately 0.7% of Redmile Group LLC’s portfolio, making the stock its 22nd largest holding. Redmile Group LLC’s holdings in DBV Technologies were worth $10,264,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of DBVT. Allworth Financial LP purchased a new stake in DBV Technologies during the fourth quarter valued at about $32,000. Royal Bank of Canada purchased a new position in shares of DBV Technologies in the fourth quarter worth approximately $34,000. GAMMA Investing LLC raised its holdings in shares of DBV Technologies by 38.4% during the fourth quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after acquiring an additional 744 shares during the period. Truvestments Capital LLC raised its holdings in shares of DBV Technologies by 71.3% during the fourth quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after acquiring an additional 1,620 shares during the period. Finally, Persistent Asset Partners Ltd purchased a new stake in shares of DBV Technologies in the 4th quarter valued at approximately $115,000. 71.74% of the stock is owned by hedge funds and other institutional investors.

DBV Technologies Trading Down 2.9%

Shares of NASDAQ:DBVT opened at $13.50 on Wednesday. The firm has a market cap of $799.34 million, a price-to-earnings ratio of -3.85 and a beta of -0.95. DBV Technologies S.A. has a 1 year low of $8.51 and a 1 year high of $26.18. The business has a fifty day simple moving average of $16.35 and a 200 day simple moving average of $19.26.

DBV Technologies (NASDAQ:DBVT) last issued its earnings results on Thursday, July 16th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.48). DBV Technologies had a negative return on equity of 119.33% and a negative net margin of 3,506.53%.The firm had revenue of $0.70 million during the quarter, compared to analyst estimates of $0.90 million. On average, sell-side analysts forecast that DBV Technologies S.A. will post -2.05 EPS for the current year.

Analyst Ratings Changes

Several research firms have weighed in on DBVT. Weiss Ratings cut shares of DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 17th. Citigroup restated an “outperform” rating on shares of DBV Technologies in a report on Friday, May 1st. Guggenheim reaffirmed a “buy” rating and issued a $51.00 target price on shares of DBV Technologies in a research report on Monday, May 4th. Citizens Jmp lifted their price target on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a report on Tuesday, June 30th. Finally, Wall Street Zen lowered DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $48.50.

DBV Technologies Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.